Phase IV adaptive randomised clinical trials evaluating efficacy and cost-efficacy of pre-emptive pharmacogenetic genotyping strategies in the Spanish National Health System: iPHARMGx Master Protocol and PREVESTATGx nested clinical trial.

doi:10.1136/bmjopen-2024-089823

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Phase IV adaptive randomised clinical trials evaluating efficacy and cost-efficacy of pre-emptive pharmacogenetic genotyping strategies in the Spanish National Health System: iPHARMGx Master Protocol and PREVESTATGx nested clinical trial.

BMJ open - 7 Nov 2024

Stewart Stefan, Seco-Meseguer Enrique, Diago-Sempere Elena, Marín-Candón Alicia, Carmona Montserrat, Estébanez Miriam, López-Fernández Luis A, Imaz-Iglesia Iñaki, Del Mar García Saiz María, Laserna-Mendieta Emilio J, Peiró Ana M, Farré Magí, Rodriguez-Jimenez Consuelo, Saiz-Rodriguez Miriam, Sanabria-Cabrera Judith, Rosas-Alonso Rocío, Abad-Santos Francisco, Pedrosa Lucia, Carcas Antonio J, García García Irene, Borobia Alberto M

Abstract excerpt

INTRODUCTION: Genetic variations impact drug response, driving the need for personalised medicine through pre-emptive pharmacogenetic testing. However, the adoption of pre-emptive pharmacogenetic testing for commonly prescribed drugs, such as statins, outside of tertiary hospitals is limited due to a lack of pharmacoeconomic evidence to support widespread implementation by healthcare policy-makers. The Spanish...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cardiovascular Diseases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cost-Benefit Analysis

Share to Genotype

Share to Hydroxymethylglutaryl-CoA Reductase Inhibitors

Share to Pharmacogenomic Testing

Share to Precision Medicine

Share to Randomized Controlled Trials as Topic

Share to Spain

Source

Open in PubMed Open full text

Identifiers

PMID: 39510769
DOI: 10.1136/bmjopen-2024-089823
PMCID: PMC11552584

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase IV adaptive randomised clinical trials evaluating efficacy and cost-efficacy of pre-emptive pharmacogenetic genotyping strategies in the Spanish National Health System: iPHARMGx Master Protocol and PREVESTATGx nested clinical trial.PMID 39510769Read ↗

Multicentre, controlled, randomised and single-blind, adaptive phase IV protocol to evaluate effectiveness and cost-effectiveness of a pre-emptive genotyping strategy to optimise tacrolimus dosage in a pretransplant chronic kidney disease population cohort: iPHARMGx TRANSPGx nested clinical trial.Semantic proximity Read ↗

A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study.Semantic proximity Read ↗

Estimation of the benefit from pre-emptive genotyping based on the nationwide cohort data in South Korea.Semantic proximity Read ↗

Pharmacogenomics implementation in cardiovascular disease in a highly diverse population: initial findings and lessons learned from a pilot study in United Arab EmiratesSemantic proximity Read ↗

Use of Drugs With Actionable Pharmacogenetic Biomarkers and Possible Prescribing Changes Among Older People.Semantic proximity Read ↗

Genotype-Guided vs Conventional Oral P2Y12 Inhibitors in Acute Coronary Syndrome: A Combined Analysis of TAILOR-PCI and POPular Genetics.Semantic proximity Read ↗

Implementing a Pharmacogenomic-driven Algorithm to Guide Antiplatelet Therapy among Caribbean Hispanics: A non-randomized prospective cohort studySemantic proximity Read ↗

Target trial emulation for a two-arm, parallel, stratified pragmatic RCT of CABG versus PCI in people with high-risk characteristics requiring myocardial revascularisation (High-Risk REVASC)Semantic proximity Read ↗

Computable Phenotype Implementation for a National, Multicenter Pragmatic Clinical Trial: Lessons Learned From ADAPTABLE.Semantic proximity Read ↗

Biobank scale pharmacogenomics informs the genetic underpinnings of simvastatin useSemantic proximity Read ↗

Implementation of Pre-emptive Pharmacogenomics Testing in Outpatient Clinics in Asia (IMPT study)Semantic proximity Read ↗

Pharmacogenetics in randomized controlled trials: considerations for trial design.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.